EGFR antagonist, Cetuximab is used in cases of (LQ)
|A||Palliative t/t of head and neck cancer|
|B||Anal canal carcinoma|
|D||Small cell lung carcinoma|
· Cetuximab binds to extracellular domain of EGFR (epidermal growth factor receptor) and blocks binding of EGF and TGF (transforming growth factor alpha) thereby inducing receptor internalization
· Cetuximab can be used in all those cancers, which express EGFR – squamous cell carcinoma of head & neck, breast, lung, kidney, prostate, brain and Pancreas.
(Remember anal cancer is resistant to chemotherapy).